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The GPR139 reference agonists 
1a and 7c, and tryptophan and 
phenylalanine share a common 
binding site
Anne Cathrine Nøhr  1, Willem Jespers2, Mohamed A. Shehata  1, Leonard Floryan3,  
Vignir Isberg  1, Kirsten Bayer Andersen1, Johan Åqvist2, Hugo Gutiérrez-de-Terán  2,  
Hans Bräuner-Osborne  1 & David E. Gloriam  1
GPR139 is an orphan G protein-coupled receptor expressed in the brain, in particular in the habenula, 
hypothalamus and striatum. It has therefore been suggested that GPR139 is a possible target for 
metabolic disorders and Parkinson’s disease. Several surrogate agonist series have been published for 
GPR139. Two series published by Shi et al. and Dvorak et al. included agonists 1a and 7c respectively, 
with potencies in the ten-nanomolar range. Furthermore, Isberg et al. and Liu et al. have previously 
shown that tryptophan (Trp) and phenylalanine (Phe) can activate GPR139 in the hundred-micromolar 
range. In this study, we produced a mutagenesis-guided model of the GPR139 binding site to form a 
foundation for future structure-based ligand optimization. Receptor mutants studied in a Ca2+ assay 
demonstrated that residues F1093×33, H1875×43, W2416×48 and N2717×38, but not E1083×32, are highly 
important for the activation of GPR139 as predicted by the receptor model. The initial ligand-receptor 
complex was optimized through free energy perturbation simulations, generating a refined GPR139 
model in agreement with experimental data. In summary, the GPR139 reference surrogate agonists 1a 
and 7c, and the endogenous amino acids l-Trp and l-Phe share a common binding site, as demonstrated 
by mutagenesis, ligand docking and free energy calculations.
G protein-coupled receptors (GPCRs) constitute the largest family of cell surface proteins. The human genome 
contains approximately 800 GPCR genes1. GPCRs are involved in a broad spectrum of (patho)physiological pro-
cesses2, 3 related to e.g. vision, neurotransmission, immune responses, and metabolism. GPCRs also constitute 
one of the most important drug target families as about a third of all approved drugs on the market today target 
a GPCR4, 5. Intriguingly, 121 GPCRs are non-sensory orphan receptors6 (having unknown endogenous ligands) 
that could represent yet untapped targets for novel treatments7.
GPR139 is a class A orphan GPCR8 and its mRNA is predominantly expressed in the striatum, habenula 
and hypothalamus9–12. Attempts to determine the GPR139 protein expression with radioligands have failed9, 13. 
Consistent cross-species expression of GPR139 mRNA in the striatum9–11, 14 suggests that GPR139 may play a 
role in locomotor activity. This is also supported by Liu et al. who showed that activation of GPR139 with a sur-
rogate agonist 7c (also known as JNJ-63533054) leads to decreased spontaneous locomotion activity in rats9. One 
major locomotion pathophysiology is Parkinson’s diseases. MPP+ is a toxin used in animals, which produce the 
neurological defects observed in Parkinson’s patients by degenerating dopaminergic neurons. A recent study by 
Andersen et al. showed that GPR139 agonists protect primary dopaminergic neurons against MPP+ in vitro15. 
Based on these findings, GPR139 has been hypothesized as a potential target for the treatment of diseases with 
impaired movement control, e.g. Parkinson’s disease.
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Furthermore, the GPR139 mRNA expression in hypothalamus and habenula suggests a role in the regulation 
of food consumption and/or energy expenditure12. l-Trp and l-Phe9, 16 activate GPR139, which has therefor been 
propsed to be a nutrient-sensing receptor9, 16. In support of this hypothesis, the closest homolog GPR142 is also 
activated by l-Trp and l-Phe17, 18 and activation of this receptor has been shown to lower blood glucose levels 
and increase insulin secretion in mice17, 19, 20 making it a new putative target for treatment of diabetes. Since the 
GPR139 receptor shares the same ligands and is expressed in the hypothalamus it is possible that GPR139 is also 
involved in the pathophysiology of diabetes. Furthermore, we have very recently shown that the endogenous 
POMC derived peptides ATCH, α-MSH, and β-MSH, known to be involved in energy homeostasis, also activate 
GPR139 in vitro21. Taken together GPR139 has been hypothesized as a potential target for the treatment of the 
metabolic syndrome e.g. diabetes and eating disorders.
Besides the natural aromatic amino acids l-Trp and l-Phe9, 16 and the endogenous POMC derived peptides21, 
GPR139 has been reported to bind surrogate small molecules (e.g. 1a and 7c)13, 22–26. In the present study, an ini-
tial homology model of GPR139 in complex with 1a was used to guide a site-directed mutagenesis (SDM) study 
of the GPR139 ligand binding site, which was performed on ligands 1a, 7c, l-Trp and l-Phe, bearing a common 
structure-activity relationship (SAR) profile as shown earlier26 and summarized in Fig. 1. The mutations and 
binding modes were further examined in silico using a ligand-steered homology modeling approach27, in this 
case based on cycles of molecular dynamics (MD) and free energy perturbation (FEP) on selected alanine muta-
tions28–30 used as a scoring function. From these results, a common interaction profile for the selected GPR139 
agonists was confirmed.
Results
Mutations selected from a preliminary 1a binding mode model. Docking of compound 1a in our 
preliminary GPR139 structure model indicated four residues; E1053×29, E1083×32, N2717×38 and R2446×51 with 
putative hydrogen bonds to the ligand linker (Supplementary Fig. 1a). The 1a naphthyl ring displayed a tight fit 
inside a deep hydrophobic pocket lined by F1093×33, H1875×43, and W2416×48. Binding poses with a flipped ligand 
orientations were also seen. However, the above-described pose got the highest score (−9.51 compared to −5.29) 
and is the only one that agrees with the mutation data. Therefore, we decided to only move forward with that and 
similar poses. Based on this binding pose, we selected 18 binding site mutations (of 12 residues) for pharmaco-
logical testing (Supplementary Fig. 1b). The mutations focused solely on residues in the transmembrane region, 
as none of the extracellular loops were in proximity of the ligand binding site.
Surface expression of GPR139 mutants. Cell surface expression was measured with ELISA using a 
myc-tag positioned at the extracellular N-terminal of GPR139. The myc-tagged wild-type (WT) receptor dis-
played equivalent response to 1a in the Fluo-4 Ca2+-assay (EC50 = 670 nM) as compared to the untagged WT 
receptor (EC50 = 772 nM) (Supplementary Fig. 2). Both R2446×51 mutants (alanine and methionine) lost surface 
expression, while the expression of H187A5×43 was significantly reduced (36% of WT, Fig. 2). Modestly reduced 
surface expression (>50%) was observed for the mutants L87A2×64, L87F2×64, Y163A4×61, and N271A7×38 whereas 
the remaining mutants showed WT-like or even increased surface expression compared to WT (Fig. 2).
The 1a binding site. In vitro mutation effects on ligand potencies. The ability of 1a to activate the mutant 
receptors was measured in a Fluo-4 Ca2+-assay (Supplementary Fig. 3). Complete loss-of-function was observed 
for mutants F109A3×33, F109L3×33, and N271A7×38, while 1a displayed markedly reduced potency at W241H6×48 
and H187A5×43 (Fig. 3). Noteworthy, for the H187A5×43 and N271A7×38 mutants their lower expression levels 
(36% and 53%, respectively) could also have contributed to the reduction in potency. However, 1a was equipotent 
on L87A2×64 indicating that mutants with reduced expression can sometimes still induce a normal functional 
response. All other mutations showed no significant (>10-fold) change in potency, indicating that these residues 
are not critical for 1a activity (Table 1 and Supplementary Table 1).
Figure 1. Structure of the GPR139 agonists studied herein. (a) Surrogate agonist 1a from Shi et al.23. (b) 
Surrogate agonist 7c from Dvorak et al.14, 24. (c,d) Trp and Phe from Isberg et al.16. Coloring denote chemical 
commonalities (supported by mutations herein); grey: major hydrophobic part, red: polar linkers (1a and 7c) or 
carboxyls (Phe and Trp), green: hydrophobic element unique for the larger 1a and 7c.
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In silico mutation effects on calculated binding affinities. The initial GPR139-1a structural model described above 
was optimized to take into account the mutagenesis data (see methods). This was done by means of iterative MD 
simulations, coupled to free energy perturbation (FEP) calculations as a scoring function (Supplementary Figs 4 
and 5). The three mutations to alanine that showed a significant effect and were sufficiently expressed were chosen 
for scoring, i.e. residues F109A3×33, H187A5×43 and N271A7×38. Mutation W241H6×48 also showed drastic effects 
on ligand potency, but the dynamic role of this residue (activation switch in class A GPCRs31) precluded us from 
using the data for its mutation to histidine in our model optimization.
The calculated difference in binding free energies for the mutant receptors in the first and second iterations 
did not correlate well with the experimental mutagenesis data, and the analysis of the trajectories showed unstable 
protein (iteration 2) and ligand (iteration 1 and 2) conformations. The third MD/FEP iteration showed significant 
effects for mutants F109A3×33 and N271A7×38, while the H187A5×43 displayed a large standard error of the mean 
(s.e.m.) (Table 2). For this reason, we ran a final iteration consisting of re-docking and MD/FEP of 1a in the con-
formation of GPR139 obtained after a similar iteration with ligand 7c (see next section). The obtained final model 
reproduced the in vitro potency data of 1a by showing positive contributions to the binding free energies (which 
corresponds to lower ligand affinity) and showed that the FEP scoring approach was able to distinguish between 
low (iteration 1) and high (iteration 4) quality models.
Binding mode in the receptor model. The 1a naphthyl ring was positioned in a deep hydrophobic pocket lined 
by F109A3×33, H187A5×43, and W241H6×48 (Fig. 4a); all of which displayed significant effects upon mutation. The 
available SAR for 1a confirms tight binding of the naphthyl ring, as substitution in the 4, 5 or 7 positions abol-
ishes ligand binding affinities23. The linker in 1a displayed hydrogen bonds to N2717×38 and R2446×51. Notably, 
the model did not show a hydrogen bond to E1083×32, but instead an indirect interaction via R2446×51. This is in 
agreement with the mutation data that showed no effect for E108A3×32 and a modest 6-fold potency reduction for 
E108Q3×32, in which the carboxamide nitrogen may have unfavorable contact with R2446×51.
Figure 2. Total and surface expression of GPR139 mutants. Cell surface expression profiles of each of the 
human GPR139 mutants compared to myc-GPR139(WT). Grey bars = total expression (triton-X treated), black 
bars = surface expression. Data is mean ± S.E.M. of 4–8 independent experiments performed in triplicates. 
Statistical analysis was performed on the surface expression using one-way ANOVA followed by Dunnett’s post-
hoc test in comparison with the surface expression of myc-GPR139(WT) (*P < 0.01).
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Figure 3. Effects of GPR139 mutations on pharmacological profiles of 1a and 7c. The data demonstrates 
that the residues F1093×33, H1875×43, W2416×48 and N2717×38 are important for GPR139 activation by 1a 
and 7c, whereas residue E1083×32 is not. Concentration-response curves of (a) 1a and (b) 7c, on the mutants 
with an effect (plus WT, mock and E108A3×32). The graphs are one representative (mean ± S.D.) out of three 
independent experiments performed in (a) triplicates and (b) duplicates. All responses are normalized to myc-
GPR139(WT) (0% = buffer, 100% = 8 μM 1a or 100 μM 7c).
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The 7c binding site. In vitro mutation effects on ligand potencies. All mutants that had an effect on 1a also 
affected 7c potency, although F109L3×33 and H187A5×43 displayed a milder (yet ~100-fold) effect (Table 1).
In silico mutation effects on calculated binding affinities. Compound 7c was docked in the optimized structure 
of GPR139 obtained from iteration 3 of the GPR139-1a complex, resulting in similar poses for the two ligands. 
Mutant % SE
1a 7c l-Trp l-Phe
pEC50 ± SEM Emax ± SEM pEC50 ± SEM Emax ± SEM pEC50 ± SEM Emax ± SEM pEC50 ± SEM Emax ± SEM
WT 100 6.63 ± 0.08 100 7.32 ± 0.16 100 3.70 ± 0.14 100 3.43 ± 0.22 100
E108A3×32 109 6.68 ± 0.11 151 ± 9 6.82 ± 0.25 112 ± 10 3.78§ 125 3.60§ 127
F109A3×33 146 <5.1 NE* <4.0 60 ± 3** <2 60 ± 10# <1.5 60 ± 6##
F109L3×33 96 <5.1 42 ± 16* 5.40 ± 0.07 102 ± 3 <2 60 ± 5# <1.5 72 ± 9##
H187A5×43 36 <5.1 35 ± 5* 5.18 ± 0.06 60 ± 9 ND ND ND ND
W241H6×48 112 <5.1 27 ± 10* <4.0 12 ± 3** <2 NE# <1.5 NE##
N271A7×38 53 <5.1 NE* <4.0 NE** <2 31 ± 5# <1.5 38 ± 9##
Table 1. GPR139 mutant potencies for 1a, 7c, l-Trp, and l-Phe. The table displays the mutants with effect on 1a 
(and E108A3×32), and a percent surface expression (% SE, normalized to WT = 100%) over 35%. The potencies 
are presented as mean pEC50 ± SEM and mean Emax ± SEM. The potency of 1a was calculated from three 
independent experiments conducted in triplicates, and normalized to buffer (0%) and 8 μM 1a (100%). The 
potencies of 7c, Trp and Phe are from three independent experiments conducted in duplicates, and normalized 
to buffer (0%) and 100 μM 7c or 10 mM Trp or 30 mM Phe (100%), respectively. Remarks: *at 8 μM, **at 
100 μM, #at 10 mM, ##at 30 mM, §only one experiment, ND: not determined (not measured) and NE: no effect 
(loss of activity).
Mutation
Change of in vitro potency In silico relative binding free energies (ΔΔG kcal/mol)
1a 7c
1a 1a 7c
Iteration 1 Iteration 2 Iteration 3 Final model Final model
F109A3×33 Loss of function
>2000 fold 
decreased −3.14 ± 0.84 0.66 ± 2.02 1.25 ± 1.03 6.52 ± 0.87 6.27 ± 0.66
H187A5×43 >34 fold decreased
138 fold 
decreased −3.03 ± 1.04 −1.26 ± 1.60 0.56 ± 1.11 2.64 ± 0.93 1.72 ± 1.29
N271A7×38 Loss of function
Loss of 
function 0.25 ± 0.47 4.40 ± 0.54 3.73 ± 0.29 3.21 ± 0.45 2.71 ± 0.34
Table 2. GPR139 in silico mutant effects of 1a and 7c binding. Iterative procedure of model optimization 
using molecular dynamics and the relative binding free energies obtained by free energy perturbation (FEP) 
calculations in comparison with in vitro potency as a scoring function. The FEP relative binding free energies 
that are in agreement with in vitro data are shown in bold.
Figure 4. 1a, 7c, l-Trp, and l-Phe binding pose models. (a) Binding mode of 1a (blue) and 7c (yellow) and 
(b) endogenous amino acids l-Trp (cyan) and l-Phe (magenta). Mutations that showed a significant effect 
when mutated are colored orange. Residues with thick sticks have been mutated in silico and in vitro (F1093×33, 
H1875×43 and N2717×39) and those with thin sticks in vitro only (W2416×48). The latter was excluded due to the 
dynamic role of this residue as an activation switch in class A GPCRs25. Residues colored in grey showed no 
significant changes in potency (E1083×32) and those in black were not expressed respectively (R2446×51). (c) 
Overlay of all four studies ligands within the GPR139 binding pocket shown as a surface. All tested agonists 
bind a deep hydrophobic pocket and are shown to undergo hydrogen bonding with R2446×51.
www.nature.com/scientificreports/
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However, during the equilibration phase of the subsequent run of MD/FEP the ligand 7c readjusted its initial pose 
to bind deeper in the binding pocket. This resulted in a stable conformation that gives calculated energies in excel-
lent agreement with the in vitro results for this ligand (Table 2). Thus, we re-docked 1a in the resulting structure 
of GPR139 and ran a final (fourth, see above) MD/FEP iteration for this ligand, obtaining excellent qualitative 
agreement with the experimental data as outlined above (Table 2). The two ligands thus show very similar effects 
for each of the three mutations considered both in vitro and in silico. Notably, the experimental data on ligand 
potency for 7c shows a somewhat milder effect for H187A5×43 than F109A3×33 and N271A7×38, which is in line 
with the lower calculated effect of the H187A5×43 mutation.
Binding mode in receptor model. The final poses for 1a and 7c overlap nearly perfectly (common scaffold RMSD 
0.529 Å, Fig. 4a) and they display nearly identical receptor interactions. This reflects their high similarity in both 
the in vitro and in silico mutants. This confirms a common binding mode for these two ligands.
The l-Trp and l-Phe binding site. In vitro mutation effects on ligand potencies. The mutations displayed 
very similar effects on the amino acids l-Trp and l-Phe as for 1a and 7c (Table 1 and Supplementary Fig. 6).
Binding mode in receptor model. Both amino acids showed a similar binding mode (Fig. 4b), placing the hydro-
phobic functional groups of the amino acids deeply in the binding pocket in overlay with hydrophobic moieties of 
1a and 7c (Fig. 4c). Furthermore, the charged backbone functionalities overlap with the polar linkers of 1a and 7c.
Discussion
We identified a common binding site for the GPR139 surrogate agonists; 1a, 7c and the endogenous amino acids 
l-Trp and l-Phe (Fig. 4). The proposed binding pocket consists of a deeply buried hydrophobic region between 
F1093×33 H1875×43 and W2416×48, and a polar region defined by N2717×38, R2446×51 and E1083×32. The four lig-
ands position themselves in a way that all have an aromatic moiety in the deep hydrophobic region, while their 
polar (1a and 7c) or charged (amino acids) regions bind to N2717×38 and R2446×51. This is supported by the loss 
of ligand activity in analogs lacking one of these carbonyls23, 24. E1083×32 is indicated to have only indirect inter-
action via R2446×51.
The binding mode matches our recent 3D pharmacophore of different series of GPR139 agonists16, 26. One of 
the two hydrophobic pharmacophore elements harbors the same ligand moieties (1a naphthyl, 7c phenyl and 
l-Phe/l-Trp sidechains) deep in the hydrophobic part of the binding site. R2446×51 and pharmacophore hydrogen 
bond acceptor elements both match the polar linkers (1a and 7c) or charged amino acids backbones. The second 
terminal phenyl in 1a and 7c points to the top of TM2, in contact with Phe832×60 and Leu862×63. A hydrogen bond 
acceptor functionality in this ring assigned by the pharmacophore model could correspond with the interaction 
of the methoxy in 1a or the chloride atom in 7c with N2717×38.
FEP calculation dependence of the use of starting structure was traditionally considered a limiting factor for 
the widespread application of this technique. However, current computational power and the increased robust-
ness of the protocols have made it possible to use the FEP results as a filter to discriminate the most reliable bind-
ing mode from a pool of solutions28. In this work, we applied FEP to refine an initial binding mode in an iterative 
fashion. This iterative protocol allowed for the identification of a binding mode that correlates with and provides 
satisfactory explanation to the experimental data. As shown in iteration 1, this effect could not be captured with 
a more simple and intuitive use of docking and modeling.
Conclusions
Our combined in vitro and in silico mutagenesis demonstrates that residues F1093×33, H187A5×43, and N2717×38 
are highly important for all studied ligands. We provide (Supplementary Data) highly refined GPR139-ligand 
complex structure models that fully agree with these data and may serve to guide future mutagenesis or ligand 
design, including identification of much needed antagonists with increased potency and selectivity. Hence, this 
first report of the GPR139 binding site paves the way for future studies towards the characterization of GPR139 
pharmacology and function.
Methods
Receptor mutagenesis. To study the influence of specific amino acids in the predicted binding pocket on 
receptor function, the desired mutations were introduced into an N-terminally c-myc-tagged wild type human 
GPR139 (NM_001002911.3) in the pEGFP-N1 vector (BD Biosciences)32, 33. As previously described33, these 
plasmids carry the signal peptide of mGluR5 to promote cell surface expression followed by a c-myc epitope to 
enable detection of total and surface expression by ELISA, followed by an engineered MluI and NotI site for easy 
insertion of the receptor of interest. Furthermore, the start-codon in the GPR139 sequence was deleted to ensure 
c-myc-tagging. Mutagenesis was designed in Serial Cloner 2.6 (© Franck Perez [SerialBasics]) and carried out by 
GenScript (USA). All mutated residues are illustrated in Supplementary Fig. 1b. An untagged GPR139(WT) in 
pEGFP-N1 was also generated to ensure that the c-myc-tag had no influence on GPR139(WT) function.
Transfection and cell culture. All GPR139 mutants were transfected into HEK293 cells. The HEK293 cells 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, 41965) supplemented with 10% dialyzed 
fetal bovine serum (Gibco, 26400, United States origin), 100 units/mL penicillin and 100 μg/mL streptomycin 
(Gibco, 15140). HEK293 cells were reverse transfected using Lipofectamine2000 (Invitrogen). More specifi-
cally two mixtures were made: 1) 10 ng DNA/well + 25 μL Opti-MEM/well and 2) 250 μg Lipofectamine2000/
well + 25 μL Opti-MEM/well. The two mixtures were mixed and 50 μL/well was added directly in black 96-well 
plates with flat clear bottoms for the Fluo-4 Ca2+-assay (Corning, Falcon, 353219) or in white Opaque 96-well 
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Microplate (PerkinElmer Life, 6005680) for ELISA. 100 μL containing 20,000 cells were added to each well and 
incubated 48 hours before assays. All plates were coated with poly-d-lysine.
ELISA. Cells were fixed using 50 μL/well 4% paraformaldehyde for 5 minutes (min). The wells were washed 
twice with DPBS (Gibco, 14190) containing 1 mM Ca2+ (DPBS-Ca), followed by addition of either 50 μL/well 
0.1% triton-X (for detection of total expression) or 50 μL/well DPBS-Ca (for detection of surface expression) 
for 5 min. The wells were again washed twice with DPBS-Ca, followed by the addition of 100 μL/well blocking 
solution (ddH2O with 3% skim milk, 1 mM Ca2+, 50 mM Trizma hydrochloride solution pH 7.4) and incubated 
at room temperature (RT) for 30 minutes. After blocking, 75 μL/well 1:1000 c-myc mouse monoclonal antibody 
(Invitrogen, R950-25) diluted in blocking solution was added to each well and incubated at RT for 45 minutes. 
Subsequently, each well was washed with 100 μL/well blocking solution and twice with 100 μl/well DPBS-Ca. 
Then 75 μL/well 1:1500 sheep anti-mouse IgG HRP conjugate (VWR, NA931-100UL) diluted in blocking solu-
tion was added, and incubated at RT for 45 minutes. The wells were then washed four times with 100 μL/well 
blocking solution and four times with 100 μL/well DPBS-Ca. At the end 65 μL/well DPBS-Ca was added, and the 
detection solution was prepared (SuperSignal ELISA Femto stable peroxidase solution and SuperSignal ELISA 
Femto luminol enhancer solution (Thermo Fisher Scientific, Waltham, MA), 1:1); 15 μL/well detection solution 
was added to the plate, and chemiluminescence was measured immediately on an EnSpire reader (PerkinElmer 
Life and Analytical Sciences).
Ligands. Compound 1a (1a) was kindly provided by H. Lundbeck A/S, Denmark. Compound 7c (Enamine, 
Z31449867) was tested as a racemate, as the (S)-form described by Janssen et al. was not commercially available. 
Both compounds were dissolved to 20 mM in DMSO (Sigma, D2650) and subsequently diluted in a HEPES buffer 
(HBSS (Gibco, 14025) supplemented with 20 mM HEPES + 1 mM MgCl2 + 1 mM CaCl2, pH = 7.4) to a final con-
centration of 0.5% DMSO in the Fluo-4 Ca2+-assay. The DMSO level was kept constant for all concentrations of 
both compounds. DMSO was confirmed not to have any activity by itself at this concentration16. l-Trp (T0254) 
and l-Phe (P2126) were obtained from Sigma-Aldrich and dissolved in buffer.
Fluo-4 Ca2+-assay. The Ca2+ measurements were preformed using the Fluo-4 NW Calcium Assay Kit 
(Invitrogen, Molecular Probes, F36206) as previously described26. Briefly, the Fluo-4 dye loading solution was 
prepared according to the manufacturer’s instructions by dissolving it in HEPES-buffer supplemented with 
2.5 mM probenecid. 50 μL dye loading solution was added to each well. Cells were incubated with the Fluo-4 dye 
for 60 min at 37 °C, then washed with 100 μL HEPES-buffer. 100 μL HEPES-buffer supplemented with 2.5 mM 
probenecid was then added to each well and incubated in 10 minutes at 37 °C before measurement. 33 μL of 1a, 
7c, l-Trp or l-Phe (4x concentrated) were added automatically after baseline measurements. Intracellular calcium 
changes were recorded as indicated on either a NOVOstar (BMG Labtech) at 37 °C with an excitation filter of 
485 nm and an emission filters 520 nm or a FlexStation 3 Benchtop Multi-Mode Microplate Reader (Molecular 
Devices) at 37 °C with an excitation wavelength of 485 nm and emission of 525 nm.
Data analysis and statistics. All pharmacological data have been analyzed by using Prism 6.0 (GraphPad 
Software Inc., San Diego). Fitting of concentration response curves was performed by non-linear regression 
log(agonist) vs. response (four parameters). Pooled data are shown with standard error of the mean (S.E.M.) 
and data showing one representative are shown with standard deviation (S.D.). Changes in potency (pEC50) and 
span of myc-GPR139(WT) in comparison to untagged GPR139(WT) was statistically analyzed with a paired 
t-test and significance was accepted at p < 0.05. The ELISA data were normalized to surface expression of 
myc-GPR139(WT) (100%). The changes in cell surface expression of GPR139 mutants in comparison with WT 
control and the changes in potency of GPR139 mutants in comparison with WT control were statistically ana-
lyzed with one-way analysis of variance (ANOVA) and Dunnett’s post-hoc test.
Homology modeling. The crystal structure of the active human serotonin 2B receptor (5HT2B - PDB: 
4IB4)34 was selected as an initial template using the online GPCRdb template selection tool35, 36. The structure has 
a resolution of 2.7 Å, and the protein sequence similarity between GPR139 and the template structure is 42% in 
the seven trans-membrane helical (7TM) region. The protein sequences of the template and target were aligned 
with MEGA637, while utilizing GPCRdb sequence alignment and the main template as a reference for assigning 
the seven helical tips. The overall receptor structure was built with Modeller9 v.1338, and loops further refined 
with the LoopModel routine therein implemented. In general, a disulphide bridge between ECL2 Cys45×50 and 
Cys3×25 is a conserved feature among most Class A GPCRs. However, this feature was not incorporated in our 
GPR139 model, as both ECL2 and TM3 lack a Cys residue in those positions. To enhance the GPR139 model for 
subsequent ligand docking, the rotamers of residues that are not conserved between the target and template were 
manually defined based on the most homologous template from an in-house GPCR position-specific rotamer 
library that contains rotamers extracted from all published GPCR crystal structures39. Therefore the rotamers of 
the following residues were refined: Y331×39, L361×42, L862×63, E1053×29, F1093×33, I1845×40, W2416×48, I2486×55, 
H2516×58, H2647×31, D2687×35, N2717×38, and L2757×42. All rotamers were collected from our in-house GPCR 
position-specific rotamer library39. On the other hand, the rotamer of R2446×51 – a critical amino acid in the bind-
ing site with no available rotamers in our library – was refined based on the rotamer library available in Maestro 
(Schrödinger Release 2015-3)40. In total, 12 of 18 residues (~67%) were refined in accordance with a similar 
crystal structure template. The quality of the model was assessed by Ramachandran plots within the PROCHECK 
webserver41.
Another homology model based on the inactive human opioid kappa receptor (OPRK - PDB: 4DJH)42 was 
also built. The template structure has a resolution of 2.9 Å, and an overall 7TM similarity of 42% to GPR139. The 
model was built and its quality assessed using the same software and routines as described above.
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Ligand Docking and Molecular Visualization. The two homology models were prepared for docking 
studies with the Schrödinger Protein Preparation Wizard, including a hydrogen optimization at pH = 7 of the 
ionisable polar groups using Maestro PROPKA43.
Docking was done with Glide44–46 with default settings. The partial charges of the ligand were assigned by 
Epik47, 48 using the OPLS_3 force field. Further options were set to allow the rotation of hydroxyl hydrogen atoms 
in the binding site, enhance the planarity of conjugated π-systems, and to include the Epik state penalties to 
the scoring calculations. Flexible ligand sampling was applied combined with biased sampling of amide groups 
(penalization of nonplanar conformations). The docking grid centroid was placed around binding pocket res-
idues E1053×29, F1093×33, W2416×48, and R2446×51, and the cubic grid box sides were set at 10 Å. Subsequently, 
the resulting receptor–ligand complexes were minimized using the energy minimization tool in MacroModel 
Schrödinger49. The TNCG (Truncated Newton Conjugate Gradient) minimization method was used with maxi-
mum iteration steps set to 5000, and with a convergence gradient of 0.001. Heavy atoms were strained at a ±0.3 Å 
radius while applying a force constant of 120 kcal/mol/Å2. Poses correlating with the mutation data were used for 
further MD analysis. All 3D images were produced in PyMOL50.
Membrane insertion and equilibration. Ligand receptor complexes obtained in the previous stage were 
inserted in the membrane and equilibrated under periodic boundary conditions (PBC) using the PyMemDyn 
protocol described elsewhere51. Shortly, the starting structure is automatically embedded in a pre-equilibrated 
membrane consisting of POPC (1-palmitoyl-2-oleoyl phosphatidylcholine) lipids, with the TM bundle aligned 
to its vertical axis. This hexagonal-prism shaped box is then soaked with bulk water and energy minimized with 
GROMACS 4.651, 52, using the OPLS-AA force field53 for protein and ligands, combined with the Berger param-
eters for the lipids54. The same setup is used for a 2.5 ns MD equilibration, where initial restraints on protein and 
ligand atoms are gradually released as described in detail in ref. 51.
MD and FEP calculations. The MD software Q55 was used for free energy perturbation (FEP) calculations 
under spherical boundary conditions, using a 25 Å sphere centered on the center of geometry of the ligand. 
Protein atoms in the boundary of the sphere 22–25 Å outer shell) had a positional restraint of 20 kcal/mol/Å2, 
while solvent atoms were subject to polarization and radial restrains using the surface constrained all-atom sol-
vent (SCAAS)56, 57 model to mimic the properties of bulk water at the sphere surface. Atoms lying outside the 
simulation sphere are tightly constrained (200 kcal/mol/Å2 force constant) and excluded from the calculation of 
non-bonded interactions. Long range electrostatics interactions beyond a 10 Å cut off were treated with the local 
reaction field method58, except for the atoms undergoing the FEP transformation where no cutoff was applied. 
Solvent bond and angles were constrained using the SHAKE algorithm59. The consideration of the binding site 
region under spherical boundary conditions offers several advantages over the alternate periodic boundary con-
ditions for free energy calculations. Besides the obvious reduction in system size, it avoids possible larger scale 
conformational fluctuations distal to the binding site. Such fluctuations commonly introduce noise and decrease 
convergence for the free energy calculations, while a spherical system still considers the relevant fluctuations in 
the binding site, as previously demonstrated60. In the particular case of membrane proteins, we have recently 
reported a similar effect when increasing the sphere size to consider distal parts of the receptor and membrane 
environment26.
All titratable residues outside the sphere were neutralized and protonation states of the histidines were man-
ually assigned. Histidine residues H1133×37, H1875×43, H2516×58, and H2647×31 were assigned a hydrogen atom 
on the δ nitrogen and residues H1323×56, H13734×54, H1803×36, and H1813×37 on the ε nitrogen. Ligand and lipid 
parameters were obtained from the previous MD stage, whereas residue parameters were translated from the 
latest version of the OPLSAA force field61.
The sphere was equilibrated for 0.61 nanoseconds, where temperature was increased from 0.1 to 298 K whilst 
slowly removing a 25 kcal/mol/Å2 restraint on all atoms, and the protein-ligand interactions maintained through 
a distance restraint (15.0 kcal/mol/Å2 force constant for distance between 1.8 and 2.2 Å) for hydrogen bonds 
between carbonyl atoms in the ligand and hydrogen atoms in R2446×51 and N2717×38. These restraints were grad-
ually removed during an additional 2 nanosecond equilibration MD, before the data collection period. This phase 
consisted of 14 replicates with different initial velocities and a 0.25 nanosecond unbiased equilibration period 
for each amino acid mutation, before applying the FEP protocol for amino acid mutations as previously pub-
lished28–30. Briefly, a given mutation of any residue to alanine is divided in several smaller subperturbations to 
allow for a smoother transition between the end-states. Three steps are introduced for groups of atom (charge 
groups) starting with the group with the highest topological distance (number of atoms) from the protein back-
bone: (i) removal of partial charges per charge group, (ii) the introduction of a soft core van der Waals potential 
and (iii) the full annihilation of the atom(s). The last step includes the introduction of the Cβ hydrogen atom of 
the alanine residue. A mutation consists of eight, seven and five subperturbations of 51 λ windows of 10 ps each 
for phenylalanine, histidine and asparagine mutations, respectively. In the final models (iterations three and four) 
we tripled the simulation time to increase the convergence and hysteresis.
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